Literature DB >> 20813762

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.

S J Wilson1, D J Nutt, C Alford, S V Argyropoulos, D S Baldwin, A N Bateson, T C Britton, C Crowe, D-J Dijk, C A Espie, P Gringras, G Hajak, C Idzikowski, A D Krystal, J R Nash, H Selsick, A L Sharpley, A G Wade.   

Abstract

Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other health care practitioners. These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment. A consensus meeting was held in London in May 2009. Those invited to attend included BAP members, representative clinicians with a strong interest in sleep disorders and recognized experts and advocates in the field, including a representative from mainland Europe and the USA. Presenters were asked to provide a review of the literature and identification of the standard of evidence in their area, with an emphasis on meta-analyses, systematic reviews and randomized controlled trials where available, plus updates on current clinical practice. Each presentation was followed by discussion, aimed to reach consensus where the evidence and/or clinical experience was considered adequate or otherwise to flag the area as a direction for future research. A draft of the proceedings was then circulated to all participants for comment. Key subsequent publications were added by the writer and speakers at draft stage. All comments were incorporated as far as possible in the final document, which represents the views of all participants although the authors take final responsibility for the document.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813762     DOI: 10.1177/0269881110379307

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  126 in total

Review 1.  Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people.

Authors:  Carlos H Rojas-Fernandez; Yannan Chen
Journal:  Can Pharm J (Ott)       Date:  2014-09

Review 2.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

3.  Insomnia: chasing the dream.

Authors:  James Mitchell Crow
Journal:  Nature       Date:  2013-05-23       Impact factor: 49.962

Review 4.  Piloting cognitive-behavioral therapy for insomnia integrated with prolonged exposure.

Authors:  Peter J Colvonen; Sean P A Drummond; Abigail C Angkaw; Sonya B Norman
Journal:  Psychol Trauma       Date:  2018-09-13

5.  Circadian rhythm in the assessment of postconcussion insomnia: a cross-sectional observational study.

Authors:  Dora M Zalai; Todd A Girard; Michael D Cusimano; Colin M Shapiro
Journal:  CMAJ Open       Date:  2020-03-10

6.  Treatment options for sleep dysfunction in Parkinson's disease.

Authors:  Mary Ann Thenganatt; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

7.  Long-term effects of melatonin on quality of life and sleep in haemodialysis patients (Melody study): a randomized controlled trial.

Authors:  Marije Russcher; Birgit C P Koch; J Elsbeth Nagtegaal; Frans J van Ittersum; Pieternel C M Pasker-de Jong; E Chris Hagen; Wim Th van Dorp; Bas Gabreëls; Thierry X Wildbergh; Monique M L van der Westerlaken; Carlo A J M Gaillard; Piet M Ter Wee
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

8.  GPs' management strategies for patients with insomnia: a survey and qualitative interview study.

Authors:  Hazel Everitt; Lisa McDermott; Geraldine Leydon; Harvey Yules; David Baldwin; Paul Little
Journal:  Br J Gen Pract       Date:  2014-02       Impact factor: 5.386

Review 9.  Sublingual zolpidem (Edluar™; Sublinox™).

Authors:  Lily P H Yang; Emma D Deeks
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

10.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.